After cuts, Pfizer looks to gene therapy, immuno-oncology

Pfizer Inc. (NYSE:PFE) said it will cut an undisclosed number of R&D jobs at its Cambridge, Mass., and Collegeville, Pa., facilities. Pfizer spokesperson Dean Mastrojohn declined to say which R&D areas would be cut. The company plans to reallocate resources to areas including immuno-oncology and gene therapy.

In December 2014, Pfizer created a gene therapy unit within its rare disease research area and announced a deal with Spark Therapeutics Inc. (NASDAQ:ONCE) to develop gene therapies to treat hemophilia B (see BioCentury Extra, Dec. 8, 2014). ...